扎鲁司特对哮喘患者肺功能和生命质量的影响

目的：探讨扎鲁司特对哮喘患者肺功能和生命质量的影响及能否减少糖皮质激素的吸入剂量。方法：哮喘急性发作期患者随机分为扎鲁司特＋半量布地奈得（普米克)治疗组及全量地奈得治疗组。测定患者清晨呼吸峰流速（PEF）／PEF预计值％及昼夜PEF变异率％（△PEFR％）。哮喘非急性发作期患者在常规治疗的基础上加用扎鲁司特20mg每天2次，一月后评价清晨、傍晚PEF及生命质量变化。结果：①扎鲁司特＋半量布地奈得吸入治疗组，其清晨PEF／PEF预计值％，△PEFR％分别高于或低于全量布地奈得吸入治疗组，1－2天起效，约2周达高峰，持续4周以上，但差异均无显著性（均P＞0．05）；②扎鲁司特提高哮喘非急性发作期患者的清晨和傍晚PEF值并改善生命质量。结论：扎鲁司特改善哮喘急性发作期患者的通气功能和减少糖皮质激素的吸入剂量；改善哮喘非急性发作期患者的通气功能及生命质量。③

Influence of zafirlukast on pulmonary functions and quality of life in patients with asthma]

OBJECTIVES: To explore the influence of zafirlukast on pulmonary functions and quality of life (QOL) in patients with mild-to-moderate asthma at the stage of attack and at the stable stage. METHODS: Patients at the stage of attack were randomly divided into two groups: Group one is zafirlukast 20 mg twice daily plus inhaled the half quantity of glucocorticoid(budelade) of the Global Initiative for Asthma (GINA) standard quantity, long-effection aminophyllin 0.2 g twice daily and inhaled salbutamol when necessary; Group two: inhaled budelade of GINA standard quantity, long-effection aminophyllin 0.2 g twice daily and inhaled salbutamol when necessary). Patients' peak expiratory flow (PEF)/PEF predicted value % and delta PEFR% were determined at the second week and the forth week before and after the treatment. On the standard treatment, patients with the stable stage were added zafirlukast 20 mg twice a day. PEF values in the morning and evening and QOL were evaluated. RESULTS: After treating with zafirlukast, the PEF/PEF predicted value % and delta PEFR% in Group one were higher and lower than those of Group two respevtively. These changes were appeared in two days and were peaked in two weeks and the peak had been gone on for more than 4 weeks, but these were no significant difference between the Groups (P > 0.05); PEF values in the morning and evening in patients with the stable asthma increased 5.9% and 4.6% respectively and their QOL were improved in asthma symptoms, limitative activities, avoiding stimuli, and reacting on stimuli. CONCLUSION: Zafirlukast can improve pulmonary function, reduce the inhalation quantity of steroid in patients with mild-to-moderate asthma, and play an important role in treating and improving QOL in patients with the stable asthma.